Study of a new treatment for advanced cancers with a specific gene change
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your cancer must have a specific change (the TP53 R175H mutation) and you must have a certain immune marker (HLA-A*02:01) in your blood.
- Your cancer should be advanced (cannot be removed by surgery) and you should have tried at least one standard treatment already.
- You must be able to care for yourself (up and about more than half of the day).
- You cannot have certain other serious medical conditions (like recent heart problems, organ transplant, or another cancer in the last few years).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This trial tests a new drug called LG00313112 in people with advanced solid tumors that have a specific genetic change called TP53 Y220C. The drug is designed to target tumors with this mutation, and the study aims to see if it can help shrink or control the cancer.
This trial tests a new treatment using specially engineered immune cells (called FT836) for people with advanced solid tumors that have not responded to other treatments. It may be given alone or with chemotherapy and/or other antibody medicines. The study aims to see if this approach can shrink tumors or slow their growth.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
This trial tests an experimental cell therapy for people with advanced solid tumors that have not responded to standard treatments. It targets tumors with specific genetic markers (KRAS or NRAS G12D and HLA-A*11:01) to see if it can shrink or slow the cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.